Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Julie Alvarado

Nurse Practitioner, Primary Care Lansing, MI Nurse Practitioner

NPI 1003215260 CMS profile 10544535

2720 Pleasant Grove Rd, Lansing, MI 48910

Open in the dashboard

General payments

$5,963

371 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Julie Alvarado of Lansing, MI is reported in the CMS Open Payments database as having received $5,963 across 371 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Nurse Practitioner, Primary Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $461 26
2024 General $1,136 63
2023 General $1,300 81
2022 General $1,908 120
2021 General $1,158 81

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Julie Alvarado
  • Nurse Practitioner, Primary Care median
  • Middle half of Nurse Practitioner, Primary Care
  • National median

In program year 2025, general payments to Julie Alvarado were reported at $461. Among 4,814 Nurse Practitioner, Primary Care profiles paid that year, the median was $169 and the middle half received between $51 and $499.

Show as a table
Year Julie Alvarado Nurse Practitioner, Primary Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,158 $137 $39–$445 $132
2022 $1,908 $139 $44–$421 $149
2023 $1,300 $163 $53–$481 $160
2024 $1,136 $176 $54–$511 $164
2025 $461 $169 $51–$499 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,008 78 payments
  2. Novo Nordisk Inc $719 54 payments
  3. AstraZeneca Pharmaceuticals LP $700 23 payments
  4. Lilly USA, LLC $434 34 payments
  5. Amgen Inc. $395 29 payments
  6. Nestle HealthCare Nutrition Inc. $259 17 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $232 12 payments
  8. GlaxoSmithKline, LLC. $230 13 payments
  9. Vanda Pharmaceuticals Inc. $204 7 payments
  10. Pfizer Inc. $203 11 payments
  11. Other $1,580 93 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,948 370 payments
  2. Education $15 1 payment
Products named General payments · program years 2021–2025
  1. BREZTRI $547 12 payments
  2. Ozempic $520 41 payments
  3. VRAYLAR $481 40 payments
  4. FARXIGA $462 9 payments
  5. ZENPEP $387 23 payments
  6. Otezla $329 24 payments
  7. JARDIANCE $294 24 payments
  8. UBRELVY $289 23 payments
  9. Repatha $279 21 payments
  10. RYBELSUS $274 18 payments
  11. Other $4,583 264 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 44 drugs

Part D claims

1,089

Median for Nurse Practitioner: 389

Drug cost

$33,451

Median for Nurse Practitioner: $21,885

Branded share of claims

16.3%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 17 $11,893
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 13 $2,968
Ezetimibe Generic 11 $1,820
Atorvastatin Calcium Generic 84 $1,112
Potassium Chloride Generic 13 $1,097
Levothyroxine Sodium Generic 84 $1,077
Armour Thyroid Thyroid,pork Brand 11 $1,010
Ondansetron Odt Ondansetron Brand 19 $922
Gabapentin Generic 34 $920
Rosuvastatin Calcium Generic 32 $892

The 10 drugs with the highest cost, of 44 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$7,298

Medicare's payments for the services billed

Medicare patients

43

Average age 74

Services billed

130

27 women, 16 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 60%
Arthritis 58%
Diabetes 37%
Ischemic heart disease 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $146
$146 — —
Ozempic
  • Novo Nordisk Inc $97
$97 — —
ZENPEP
  • AIMMUNE THERAPEUTICS, INC. $94
$94 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $72
$72 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $35
  • Lilly USA, LLC $24
$59 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

371 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Primary Care in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record